Search

everythinglearnresearchcommunity

for

Search:↓

Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.

Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

As of 1994, treatments for liver cancer had not significantly improved patient survival.

Some drugs can cause reversible hair loss, but certain chemotherapy drugs may lead to permanent hair loss; drugs can also change hair color and texture.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.

Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.

Mycophenolate helps reverse hair loss effects caused by IFN-γ by activating a key hair growth pathway.

Targeting specific T cells may help treat alopecia areata.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Blocking interferon-gamma might help treat various autoimmune diseases.

The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.

Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.